Related Experiment Video
Updated: Feb 16, 2026
06:23
Localization of SUMO-modified Proteins Using Fluorescent Sumo-trapping Proteins
Published on: April 27, 2019
9.0K
Small molecule SUMOylation activators are novel neuroprotective agents
Katherine Krajnak1, Russell Dahl2
1Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Bioorganic & Medicinal Chemistry Letters
|December 23, 2017
Summary
Researchers discovered novel drug-like molecules that activate SUMOylation, a natural neuroprotective response. These compounds show promise for treating neurodegenerative diseases like Parkinson's and Alzheimer's by preventing neuronal loss.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neuronal loss is a key feature of aging-related nervous system diseases.
- Effective neuroprotective treatments are urgently needed for conditions like Parkinson's, Alzheimer's, and stroke.
- Small ubiquitin-like modifier (SUMO) conjugation is an endogenous neuroprotective mechanism.
Purpose of the Study:
- To discover and develop novel small molecules that activate SUMOylation.
- To identify drug-like SUMOylation activators through a hit-to-lead campaign.
- To validate these activators in cell-based models of neuronal loss.
Main Methods:
- Hit-to-lead campaign to identify SUMOylation activators.
- Medicinal chemistry optimization of initial hits.
- Cell-based assays to evaluate neuroprotective effects and neuronal loss.
Main Results:
- Discovery of three diverse classes of drug-like SUMOylation activators.
- Optimization of lead compounds demonstrating enhanced SUMO conjugation.
- Validation of optimized compounds in cell models of neuronal damage.
Conclusions:
- Developed novel small molecules that enhance SUMOylation.
- These compounds provide a foundation for new therapies against neurodegenerative diseases.
- Potential for systemically active SUMO activators to treat Parkinson's, Alzheimer's, and stroke.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
944
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
944
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
02:30siRNA - Small Interfering RNAs
18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K